Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03135171
Recruitment Status : Recruiting
First Posted : May 1, 2017
Last Update Posted : February 8, 2019
Sponsor:
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 1, 2019
  Estimated Study Completion Date : August 1, 2019